It's been a busy month here at the HCV and HBV Advocate Websites. We have recently posted the following important information and news items:
1. April 2012 Newsletter - In This Issue:
Drugs in Development: Update, by Alan Franciscus, Editor-in-Chief – read about the latest developments in the HCV drug pipeline including GS-7977, VX-222 and HIV/HCV coinfection studies on telaprevir and boceprevir.
HealthWise: Laughing with Liver Disease, by Lucinda K. Porter, RN- this is Lucinda’s annual April Fools HealthWise. See what tickles your funny bone.
HCV Snapshots Lucinda K. Porter, RN discusses the on-going issue of coffee and the liver, the use of erythropoietin, and transmission of HCV in the health care industry.
Disability & Benefits: Maintaining Your Disability Claim in the Internet Age, by Jacques Chambers, CLU – a must read article—most people have some type of personal information on the internet. Read about the potential harmful effects of social media on disability.
2. April 2012 HBV Journal Review, by Chris Kukka—stay updated on the latest HBV information. Below is just a small sample of the articles summarized in this month’s review:
- For Older Adults, Health Care Procedures Pose Higher Hepatitis Risk Than Sex and Illicit Drugs
- Pegylated Interferon and Adefovir Combination More Effective Than Interferon Alone
- Many Younger Patients with Liver Cancer Don't Experience Cirrhosis, So Diagnoses Are Delayed
- Doctors May Miss HBV in HIV-Infected Patients
- Hepatitis B Patients May Need Selenium Supplements
- Only 34% of Elderly Can Be Successfully Immunized Against Hepatitis B
3. Top News (Blog) from the hepatitis blog includes:
and much, much more…..
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.